

advances.sciencemag.org/cgi/content/full/6/42/eabd4596/DC1

# Supplementary Materials for

# Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti–COVID-19 drug design

Wioletta Rut\*, Zongyang Lv, Mikolaj Zmudzinski, Stephanie Patchett, Digant Nayak, Scott J. Snipas, Farid El Oualid, Tony T. Huang\*, Miklos Bekes\*, Marcin Drag\*, Shaun K. Olsen\*

\*Corresponding author. Email: wioletta.rut@pwr.edu.pl (W.R.); tony.huang@nyulangone.org (T.T.H.); miklosbekes@icloud.com (M.B.); olsens@uthscsa.edu (S.K.O.); marcin.drag@pwr.edu.pl (M.D.)

Published 16 October 2020, *Sci. Adv.* **6**, eabd4596 (2020) DOI: 10.1126/sciadv.abd4596

### This PDF file includes:

Figs. S1 to S3 Tables S1 to S3

#### Ac-Leu-Arg-P2-Gly-ACC



Supplementary Figure 1. SARS-CoV-PLpro and SARS-CoV-2-PLpro substrate specificity profiles presented as heat maps.



**Supplementary Figure 2. Comparision of apo versus VIR250 and VIR251 bound SARS-CoV-2 PLpro.** (A) The indicated structures were superimposed and are shown as ribbons. Zinc atoms are shown as spheres, colored according to their representative structure. Regions of conformational variability between apo and VIR250 and VIR251 structures are labeled including the Finger Domain, the Ub-like domain, and the β14-β15 loop. Catalytic cysteine 111 of SARS-CoV-2 PLpro is shown as sticks with its sg atom shown as yellow sphere. (B) Magnified view of the conformational differences around the β14-β15 loop of SARS-CoV-2 PLpro.



Supplementary Figure 3. Chemical structures of the Ub/Ubl activity based probes used in Figure 4B.



**Table S1**. Structures of fixed natural and unnatural amino acids used in the combinatorial library.















|  | SARS-CoV-2<br>PLpro/VIR250 complex                   | SARS-CoV-2<br>PLpro/VIR251 complex                           |
|--|--|--|
| PDB ID                                   | 6WUU   | 6WX4   |
| Source                                   | APS 24 IDC   | APS 24 IDC   |
| Wavelength (Å)                           | 0.979  | 0.979  |
| Resolution Limits (Å)                    | 94.9-2.79 (2.93-2.79)                                | 90.7-1.65 (1.68-1.65)  |
| Space Group                              | P21  | 1222   |
| Unit Cell (Å) a, b, c                    | 58.4, 189.7, 63.1                                    | 44.9, 113.5, 151.1   |
| Unit Cell (°) α, β, γ                    | 90, 98.7, 90   | 90, 90, 90   |
| Number of observations                   | 237255   | 611490   |
| Number of reflections                    | 33589 (4431)   | 46470 (2152)   |
| Completeness (%)                         | 99.6 (99.1)  | 99.5 (91.0)  |
| Mean I/σI                                | 10.1 (1.1)   | 15.5 (1.2)   |
| CC1/2                                    | 0.996 (0.437)  | 0.998 (0.531)  |
| R <sub>merge</sub> <sup>a</sup>          | 0.158 (1.79)   | 0.094 (1.73)   |
| R <sub>pim</sub>                         | 0.064 (0.753)  | 0.027 (0.513)  |
|  |  |  |
| Refinement Statistics                    |  |  |
| Resolution Limits (Å)                    | 94.9-2.79 (2.86-2.79)                                | 90.7-1.65 (1.70-1.65)  |
| # of reflections (work/free)             | 31489 (1992)   | 44301 (2000)   |
| Completeness (%)                         | 99.3 (98.0)  | 99.5 (94.0)  |
| Protein/solvent/ligand atoms             | 10122/8/144  | 2545/194/35  |
| Rcryst <sup>b</sup>                      | 0.195 (0.299)  | 0.170 (0.241)  |
| R <sub>free</sub>                        | 0.230 (0.333)  | 0.196 (0.256)  |
| Bonds (Å)/ Angles (°)                    | 0.004/0.737  | 0.006/0.844  |
| B-factors:<br>protein/solvent/ligand (Ų) | 81.2/84.8/78.2                                       | 37.7/43.5/30.6   |
| Ramachandran plot statistics (%)         |  |  |
| favored                                  | 95.3   | 97.0   |
| allowed                                  | 4.6  | 3.0  |
| outliers                                 | 0.1  | 0  |
| MolProbity score                         | 1.48- $100^{th}$ percentile (N=4482, 2.79 Å ± 0.25Å) | 1.19- 99 <sup>th</sup> percentile<br>(N=789, 1.65 Å ± 0.25Å) |

#### Supplementary Table 2. Crystallographic Data and Refinement Statistics

Parentheses indicate statistics for the high-resolution data bin for x-ray data. a.  $R_{merge} = \sum hkl \sum_{i} |l(hkl)i - \langle l(hkl) \rangle |/\sum_{hkl} i \langle l(hkl)i \rangle$ . b.  $R_{cryst} = \sum hkl |Fo(hkl)-Fc(hkl)|/\sum_{hkl} |Fo(hkl)|$ , where Fo and Fc are observed and calculated structure factors, respectively.

Table S3. Codon optimized DNA and protein sequences of CoV-2 PLpro constructs used in this study.

#### Codon optimized SARS CoV-2 PLpro [N-terminal GST tagged]- DNA sequence

#### <u>Codon optimized SARS CoV-2 PLpro [uncleavable C-terminal 6x His tag]- protein sequence after</u> <u>Precision Protease cleavage of GST tag</u>

GPLGSREVRTIKVFTTVDNINLHTQVVDMSMTYGQQFGPTYLDGADVTKIKPHNSHEGKTFYVLPNDDTL RVEAFEYYHTTDPSFLGRYMSALNHTKKWKYPQVNGLTSIKWADNNCYLATALLTLQQIELKFNPPALQD AYYRARAGEAANFCALILAYCNKTVGELGDVRETMSYLFQHANLDSCKRVLNVVCKTCGQQQTTLKGVE AVMYMGTLSYEQFKKGVQIPCTCGKQATKYLVQQESPFVMMSAPPAQYELKHGTFTCASEYTGNYQCG HYKHITSKETLYCIDGALLTKSSEYKGPITDVFYKENSYTTTIKP

#### Codon optimized SARS CoV-2 PLpro [uncleavable C-terminal 6x His tag]- DNA sequence

#### Codon optimized SARS CoV-2 PLpro [uncleavable C-terminal 6x His tag]- protein sequence

MREVRTIKVFTTVDNINLHTQVVDMSMTYGQQFGPTYLDGADVTKIKPHNSHEGKTFYVLPNDDTLRVEA FEYYHTTDPSFLGRYMSALNHTKKWKYPQVNGLTSIKWADNNCYLATALLTLQQIELKFNPPALQDAYYR ARAGEAANFCALILAYCNKTVGELGDVRETMSYLFQHANLDSCKRVLNVVCKTCGQQQTTLKGVEAVMY MGTLSYEQFKKGVQIPCTCGKQATKYLVQQESPFVMMSAPPAQYELKHGTFTCASEYTGNYQCGHYKHI TSKETLYCIDGALLTKSSEYKGPITDVFYKENSYTTTIKPLEHHHHHH

### LC-MS analysis of synthesized chemical compounds



### Ac-Leu-Arg-Gly-Gly-ACC

# Ac-Abu(Bth)-Dap-Gly-Gly-ACC





# Ac-Abu(Bth)-Dab-Gly-Gly-ACC





# Ac-hTyr-Phe(guan)-Gly-Gly-ACC





# Ac-hTyr-Dap-Gly-Gly-ACC



# Ac-hPhe-Dap-Gly-Gly-ACC





## Ac-Abu(Bth)-Dap-Gly-Gly-VME HRMS for $C_{23}H_{30}N_6O_6S$ (m/z<sub>cated</sub> = 519.2026; m/z<sub>found</sub> = 519.2034)

# Ac-hTyr-Dap-Gly-Gly-VME



### **Ub-ACC**

| charge | $m/z_{calcd}$ | $m/z_{found}$ |
|--------|---------------|---------------|
| +6     | 1461.6221     | 1461.8839     |
| +7     | 1252.9628     | 1253.2618     |
| +8     | 1096.4684     | 1096.7080     |
| +9     | 974.7505      | 974.9593      |
| +10    | 877.3762      | 877.6428      |
| +11    | 797.7063      | 797.8460      |

HRMS for  $C_{_{389}}H_{_{637}}N_{_{107}}O_{_{120}}S$ 



### **Biot-6-Ahx-Ub-VME**

### HRMS for $C_{397}H_{658}N_{108}O_{121}S_2$

| charge | $m/z_{calcd}$ | $m/z_{found}$ |
|--------|---------------|---------------|
| +6     | 1491.4778     | 1491.8063     |
| +7     | 1278.5535     | 1278.8268     |
| +8     | 1118.8602     | 1119.2485     |
| +9     | 994.6543      | 994.8820      |
| +10    | 895.2896      | 895.3971      |
| +11    | 813.9912      | 814.0791      |
| +12    | 746.2426      | 746.3508      |

